; and (2) upon granting exclusive approval or licensure under subsection (a) on the basis of a demonstration of clinical superiority as described in subsection (c), shall publish a summary of the clinical superiority findings. . (b) Rule of Construction Nothing in the amendments made by subsection (a) shall affect any determination under sections 526 and 527 of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 360bb , 360cc) made prior to the date of enactment of the Orphan Products Extension Now Accelerating Cures and Treatments Act of 2017 . 4. Pediatric information added to labeling Section 505A(o) of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 355a(o) ) is amended— (1) in the subsection heading, by striking Under Section 505(j) ; (2) in paragraph (1)— (A) by striking under section 505(j) and inserting under subsection (b)(2) or (j) of section 505 ; and (B) by striking or by exclusivity under clause (iii) or (iv) of section 505(j)(5)(F) and inserting , or by exclusivity under clause (iii) or (iv) of section 505(j)(5)(F), clauses (iii) and (iv) of section 505(c)(3)(E), or section 527(a), or by an extension of such exclusivity under this section or section 505E ; (3) in paragraph (2), in the matter preceding subparagraph (A)— (A) by inserting clauses (iii) and (iv) of section 505(c)(3)(E), or section 527, after section 505(j)(5)(F), ; and (B) by striking drug approved under section 505(j) and inserting drug approved pursuant to an application submitted under subsection (b)(2) or (j) of section 505 ; and (4) by amending paragraph (3) to read as follows: (3) Preservation of pediatric exclusivity and other provisions This subsection does not affect— (A) the availability or scope of exclusivity under— (i) this section; (ii) section 505 for pediatric formulations; or (iii) section 527